Register for the ASCO post-show roundtable: Expert takeaways from the world's biggest cancer meeting
Join us on June 1st at 3:00pm ET / 12:00pm PT. Register today.
Overview on ten new molecular entities in ongoing or planned late-stage studies
After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.
Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.
During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.